These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35496814)

  • 21. Guidance for Restarting Inflammatory Bowel Disease Therapy in Patients Who Withheld Immunosuppressant Medications During COVID-19.
    Siegel CA; Christensen B; Kornbluth A; Rosh JR; Kappelman MD; Ungaro RC; Johnson DF; Chapman S; Wohl DA; Mantzaris GJ
    J Crohns Colitis; 2020 Oct; 14(14 Suppl 3):S769-S773. PubMed ID: 33085972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate).
    Sattler L; Hanauer SB; Malter L
    Curr Gastroenterol Rep; 2021 Dec; 23(12):30. PubMed ID: 34913108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and validation of multivariable prediction models for adverse COVID-19 outcomes in IBD patients.
    Sperger J; Shah KS; Lu M; Zhang X; Ungaro RC; Brenner EJ; Agrawal M; Colombel JF; Kappelman MD; Kosorok MR
    medRxiv; 2021 Jan; ():. PubMed ID: 33501455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COVID-19 in Patients with Inflammatory Bowel Disease: The Israeli Experience.
    Lichtenstein L; Koslowsky B; Ben Ya'acov A; Avni-Biron I; Ovadia B; Ben-Bassat O; Naftali T; Kopylov U; Haberman Y; Eran HB; Eliakim R; Lahat-Zok A; Hirsch A; Zittan E; Maharshak N; Waterman M; Israeli E; Goren I; Ollech JE; Yanai H; Ungar B; Avidan B; Ben Hur D; Melamud B; Segol O; Shalem Z; Dotan I; Odes SH; Ben-Horin S; Snir Y; Milgrom Y; Broide E; Goldin E; Delgado S; Ron Y; Cohen NA; Maoz E; Zborovsky M; Odeh S; Abu Freha N; Shachar E; Chowers Y; Engel T; Reiss-Mintz H; Segal A; Zinger A; Bar-Gil Shitrit A
    Vaccines (Basel); 2022 Feb; 10(3):. PubMed ID: 35335008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications.
    Khan N; Mahmud N
    Gastroenterology; 2021 Sep; 161(3):827-836. PubMed ID: 34048782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.
    Bezzio C; Armuzzi A; Furfaro F; Ardizzone S; Milla M; Carparelli S; Orlando A; Caprioli FA; Castiglione F; Viganò C; Ribaldone DG; Zingone F; Monterubbianesi R; Imperatore N; Festa S; Daperno M; Scucchi L; Ferronato A; Pastorelli L; Balestrieri P; Ricci C; Cappello M; Felice C; Fiorino G; Saibeni S;
    Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1432-1441. PubMed ID: 34694009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inflammatory Bowel Disease during COVID-19 Pandemic: A Prospective Cohort Study of Incidence Rate and Patients' Concerns.
    Bagheri Lankarani K; Roozitalab M; Gholami Z; Yousefi M; Ghahramani S
    Middle East J Dig Dis; 2022 Jan; 14(1):24-33. PubMed ID: 36619720
    [No Abstract]   [Full Text] [Related]  

  • 28. [The gastrointestinal effects of COVID–19 infection during childhood and among the children affected with inflammatory bowel disease].
    Tóbi L; Prehoda B; Balogh A; Dezsőfi-Gottl A; Cseh Á
    Orv Hetil; 2022 Feb; 163(6):214-221. PubMed ID: 35124570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Zero COVID-19 infection in inflammatory bowel disease patients: Findings from population-based inflammatory bowel disease registries in Hong Kong and Taiwan.
    Mak JWY; Weng MT; Wei SC; Ng SC
    J Gastroenterol Hepatol; 2021 Jan; 36(1):171-173. PubMed ID: 32589798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives.
    Suria C; Bosca-Watts MM; Navarro P; Tosca J; Anton R; Sanahuja A; Revaliente M; Minguez M
    Gastroenterol Hepatol; 2022 May; 45(5):383-389. PubMed ID: 34171421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inflammatory Bowel Disease Patients' Perspectives during COVID-19 Pandemic: Results from a Portuguese Survey.
    Revés JB; Frias-Gomes C; Morão B; Nascimento C; Palmela C; Fidalgo C; Roque Ramos L; Sampaio A; Glória L; Cravo M; Torres J
    GE Port J Gastroenterol; 2021 Sep; 5(5):1-9. PubMed ID: 34934777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A machine learning approach identifies 5-ASA and ulcerative colitis as being linked with higher COVID-19 mortality in patients with IBD.
    Roy S; Sheikh SZ; Furey TS
    Sci Rep; 2021 Aug; 11(1):16522. PubMed ID: 34389789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Crohn's and Colitis Canada's 2021 Impact of COVID-19 & Inflammatory Bowel Disease in Canada: A Knowledge Translation Strategy.
    Kaplan GG; Windsor JW; Crain J; Barrett L; Bernstein CN; Bitton A; Chauhan U; Coward S; Fowler S; Ghia JE; Gibson DL; Griffiths AM; Jones JL; Khanna R; Kuenzig ME; Lakatos PL; Lee K; Mack DR; Marshall JK; Mawani M; Murthy SK; Panaccione R; Seow CH; Targownik LE; Zelinsky S; Benchimol EI
    J Can Assoc Gastroenterol; 2021 Dec; 4(Suppl 2):S10-S19. PubMed ID: 34755034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of COVID-19 on inflammatory bowel disease practice and perspectives for the future.
    Viganò C; Mulinacci G; Palermo A; Barisani D; Pirola L; Fichera M; Invernizzi P; Massironi S
    World J Gastroenterol; 2021 Sep; 27(33):5520-5535. PubMed ID: 34588749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The 2023 Impact of Inflammatory Bowel Disease in Canada: COVID-19 and IBD.
    Kaplan GG; Kuenzig ME; Windsor JW; Bernstein CN; Bitton A; Coward S; Jones JL; Lee K; Murthy SK; Targownik LE; Peña-Sánchez JN; Ghandeharian S; Rohatinsky N; Weinstein J; Jones May T; Browne M; Jannati N; Tabatabavakili S; Im JHB; Meka S; Vukovic S; Davis T; Goddard Q; Gorospe J; Stocks T; Caplan L; Kanaan N; Stuart D; Ramsay T; Robinson KJ; Charron-Bishop D; Benchimol EI
    J Can Assoc Gastroenterol; 2023 Sep; 6(Suppl 2):S76-S82. PubMed ID: 37674494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications.
    Ban L; Tata LJ; Fiaschi L; Card T
    Gastroenterology; 2014 Jan; 146(1):76-84. PubMed ID: 24126096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Risk Factors and Medications.
    Targownik LE; Bernstein CN; Lakatos PL; Murthy SK; Benchimol EI; Bitton A; Huang JG; Kuenzig ME; Jones JL; Kaplan GG; Lee K; Mukhtar MS; Tandon P; Windsor JW; Panaccione R
    J Can Assoc Gastroenterol; 2021 Dec; 4(Suppl 2):S40-S45. PubMed ID: 34755038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased risk of pneumonia among patients with inflammatory bowel disease.
    Long MD; Martin C; Sandler RS; Kappelman MD
    Am J Gastroenterol; 2013 Feb; 108(2):240-8. PubMed ID: 23295276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of COVID-19 in Patients with Inflammatory Bowel Disease: Comparison with Household Members and the Role of IBD Medications.
    Sima AR; Saberzadeh-Ardestani B; Vahedi H; Fakheri H; Mansour-Ghanaei F; Maleki I; Nasseri-Moghaddam S; Vosoghinia H; Ghadir MR; Hormati A; Kasaeian A; Radmard AR; Khosravi B; Malekzadeh M; Alatab S; Sadeghi A; Aminisani N; Poustchi H; Gonoudi E; Anushiravani A; Rayatpisheh M; Colombel JF; Ungaro RC; Malekzadeh R
    Arch Iran Med; 2022 Jan; 25(1):17-25. PubMed ID: 35128908
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.